Application potential of induced pluripotent stem cells in the research and treatment of autoimmune diseases (Review).

IF 3.5 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Molecular medicine reports Pub Date : 2025-12-01 Epub Date: 2025-10-03 DOI:10.3892/mmr.2025.13698
Zizhen Ye, Hanwei Zhao, Xuanhu Ye
{"title":"Application potential of induced pluripotent stem cells in the research and treatment of autoimmune diseases (Review).","authors":"Zizhen Ye, Hanwei Zhao, Xuanhu Ye","doi":"10.3892/mmr.2025.13698","DOIUrl":null,"url":null,"abstract":"<p><p>Autoimmune diseases are a group of disorders caused by the immune system mistakenly attacking the body's own tissues, including type 1 diabetes, rheumatoid arthritis and multiple sclerosis (MS). These diseases are typically accompanied by chronic inflammation and tissue damage, which markedly impact the quality of life of patients. Induced pluripotent stem cells (iPSCs), owing to their unlimited proliferative capacity and pluripotency, demonstrate unique advantages in the field of regenerative medicine. iPSCs can be induced to differentiate into various functional cells in vitro providing potentially important tools for disease modeling, drug screening and cell therapy. For example, iPSCs can be directed to generate cardiomyocytes, dopaminergic neurons, hepatocyte‑like cells and pancreatic β‑cells, highlighting their broad potential for translational applications. For treating autoimmune diseases, iPSCs can be utilized for tissue repair, replacement therapy and the induction of cells with immunoregulatory functions. The present review summarizes the latest advancements in iPSC technology and its research in various autoimmune diseases, including MS, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes and systemic sclerosis. The present study also discusses the main challenges in the application of iPSCs, aiming to provide a theoretical basis and practical guidance for developing novel therapeutic strategies.</p>","PeriodicalId":18818,"journal":{"name":"Molecular medicine reports","volume":"32 6","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular medicine reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/mmr.2025.13698","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Autoimmune diseases are a group of disorders caused by the immune system mistakenly attacking the body's own tissues, including type 1 diabetes, rheumatoid arthritis and multiple sclerosis (MS). These diseases are typically accompanied by chronic inflammation and tissue damage, which markedly impact the quality of life of patients. Induced pluripotent stem cells (iPSCs), owing to their unlimited proliferative capacity and pluripotency, demonstrate unique advantages in the field of regenerative medicine. iPSCs can be induced to differentiate into various functional cells in vitro providing potentially important tools for disease modeling, drug screening and cell therapy. For example, iPSCs can be directed to generate cardiomyocytes, dopaminergic neurons, hepatocyte‑like cells and pancreatic β‑cells, highlighting their broad potential for translational applications. For treating autoimmune diseases, iPSCs can be utilized for tissue repair, replacement therapy and the induction of cells with immunoregulatory functions. The present review summarizes the latest advancements in iPSC technology and its research in various autoimmune diseases, including MS, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes and systemic sclerosis. The present study also discusses the main challenges in the application of iPSCs, aiming to provide a theoretical basis and practical guidance for developing novel therapeutic strategies.

诱导多能干细胞在自身免疫性疾病研究和治疗中的应用潜力(综述)。
自身免疫性疾病是由免疫系统错误地攻击人体自身组织引起的一组疾病,包括1型糖尿病、类风湿性关节炎和多发性硬化症(MS)。这些疾病通常伴有慢性炎症和组织损伤,显著影响患者的生活质量。诱导多能干细胞(Induced pluripotent stem cells, iPSCs)由于其无限增殖能力和多能性,在再生医学领域具有独特的优势。iPSCs可以在体外诱导分化为各种功能细胞,为疾病建模、药物筛选和细胞治疗提供潜在的重要工具。例如,iPSCs可以定向生成心肌细胞、多巴胺能神经元、肝细胞样细胞和胰腺β细胞,这突出了它们在转化应用方面的广泛潜力。在自身免疫性疾病的治疗中,iPSCs可用于组织修复、替代治疗和诱导具有免疫调节功能的细胞。本文综述了iPSC技术及其在多发性硬化症、类风湿性关节炎、系统性红斑狼疮、1型糖尿病和系统性硬化症等自身免疫性疾病中的研究进展。本研究还讨论了iPSCs应用中的主要挑战,旨在为开发新的治疗策略提供理论基础和实践指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular medicine reports
Molecular medicine reports 医学-病理学
CiteScore
7.60
自引率
0.00%
发文量
321
审稿时长
1.5 months
期刊介绍: Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信